Avid Radiopharmaceuticals Revenue and Competitors

Location

$69.9M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Avid Radiopharmaceuticals's estimated annual revenue is currently $26.5M per year.(i)
  • Avid Radiopharmaceuticals's estimated revenue per employee is $201,000
  • Avid Radiopharmaceuticals's total funding is $69.9M.

Employee Data

  • Avid Radiopharmaceuticals has 132 Employees.(i)
  • Avid Radiopharmaceuticals grew their employee count by -1% last year.

Avid Radiopharmaceuticals's People

NameTitleEmail/Phone
1
Associate VP, Regulatory Affairs, Imaging Medical R&DReveal Email/Phone
2
Associate VP, Quality AssuranceReveal Email/Phone
3
ControllerReveal Email/Phone
4
Senior Director, Radiochemistry and Radiopharmaceutical DevelopmentReveal Email/Phone
5
Director, CMC RegulatoryReveal Email/Phone
6
Director, PET Analysis and Image ManagementReveal Email/Phone
7
Director, CMC Project ManagementReveal Email/Phone
8
Associate Director, PET Analysis and Image ManagementReveal Email/Phone
9
Associate Director Technical OperationsReveal Email/Phone
10
Associate Director Quality EngineeringReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M2156%N/AN/A
#2
$81.8M40710%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M2231%N/AN/A
#6
$13.1M655%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M86-5%N/AN/A
#9
$67.9M33823%N/AN/A
#10
$14.9M747%N/AN/A
Add Company

What Is Avid Radiopharmaceuticals?

Avid Radiopharmaceuticals, Inc. (Avid RP) is a product-focused molecular imaging company developing novel diagnostic agents to enable early diagnosis, treatment selection and therapeutic monitoring of serious diseases. The company is a pioneer in clinical development of agents for detecting and monitoring Alzheimer's disease, and its lead radiolabeled compounds are being developed to enable physicians to diagnose Alzheimer's in real-time and to allow Alzheimer's researchers to evaluate the many drug candidates targeting amyloid plaque build-up. Avid's technology can be used with a variety of imaging technologies such as PET and SPECT scanning and has already been tested in pilot human studies.

keywords:N/A

$69.9M

Total Funding

132

Number of Employees

$26.5M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Avid Radiopharmaceuticals News

2022-04-17 - Race of people given Alzheimer's blood tests may affect ...

She participates as a site investigator in clinical trials sponsored by Avid Radiopharmaceuticals, Eli Lilly, Biogen, Eisai, Jaansen,...

2022-04-13 - Alzheimer's Therapeutics Market Is Set to Expand at a CAGR ...

... Amarantus Bioscience Holdings, Anavex LifeSciences, Avid Radiopharmaceuticals, Axon Neuroscience, Axovant Sciences, Daiichi Sankyo Co,...

2022-04-06 - Blood Testing Reveals Amyloid-Lowering Effect of Alzheimer's ...

... PhD, vice president of clinical development at Avid Radiopharmaceuticals, the biomarker arm of Lilly, told Medscape Medical News.

2007-05-09 - Avid Radiopharmaceuticals, maker of imaging reagents, raises $26M for clinical trials

Avid Radiopharmaceuticals, a Philadelphia-based maker of “molecular imaging agents” that help highlight diseased tissue in various medical scans, raised $26 million in a third round to develop early-detection products for Alzheimer’s and Parkinson’s disease. AllianceBernstein and Safeguard Scie ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35.6M1320%N/A
#2
$23.8M1324%N/A
#3
$37.9M1327%N/A
#4
$35.6M132-4%N/A
#5
$19.8M1326%N/A